osteoarthritis – Cytonics Corporation

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

Science Corner, Our StoryJanuary 20, 2026459Views 0Likes 0Comments

Most people talk about lifespan. We obsess over how long we live. What actually matters is healthspan. How long we stay strong, mobile, and pain-free. Living to 90 means very little if your joints fail you at 60. At Cytonics Corporation, our mission is simple: extend healthspan by protecting the biology that makes movement…

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

Investor Relations, Our Story, Science CornerJanuary 6, 2026596Views 0Likes 0Comments

You may have seen the recent headlines regarding a breakthrough in "anti-aging injections" for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in joints). While the media is…

#62 🙏 Another Year Full of Gratitude

Investor Relations, Our Story, Joey BoseDecember 26, 2025511Views 0Likes 0Comments

As the year concludes, Joey Bose reflects on gratitude towards investors, the Cytonics community, and the dedicated team. He emphasizes the importance of long-term commitment and support in their progress. Looking ahead to 2026, he encourages everyone to cherish time with loved ones and appreciate their contributions.

#61 🛑 Can We Stop Osteoarthritis Before It Starts?

Science CornerDecember 20, 2025541Views 0Likes 0Comments

Some individuals inherit a genetic risk for osteoarthritis, potentially experiencing severe symptoms by their 40s or 50s. Early identification and treatment with alpha-2-macroglobulin (A2M) may preserve joint health and enhance quality of life. Development of CYT-108 aims to target the root cause of osteoarthritis, rather than just alleviate pain.

#60 👎 Where Big Pharma Tried And Failed

Science CornerNovember 4, 2025633Views 0Likes 0Comments

Osteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials.

#59 🧬 Why is A2M being called a physiological guardian?

UncategorizedOctober 21, 2025647Views 0Likes 0Comments

Joey Bose, our CEO and President, breaks down why researchers have called A2M the 'physiological guardian.' A2M, or alpha-2-macroglobulin, is a natural protein found in your bloodstream that acts like a bodyguard against inflammation and joint destruction. It works as a broad-spectrum protease inhibitor and also sequesters cytokines – the same inflammatory signals you heard…

#58 🚅 Inside the Engine Room: Progress Since Our $7M Raise

Investor RelationsOctober 14, 2025414Views 0Likes 0Comments

How Cytonics is preparing for its next regulatory milestone — from database lock to FDA engagement. It’s been just over a month since we wrapped up our $7M crowdfunding campaign — our largest and most successful raise to date — and the pace hasn’t slowed for a moment. Since then, our team has been hard…

#57: 👎 Why Cytonics Turned Down VC

Investor Relations, Our StoryAugust 27, 2025625Views 0Likes 0Comments

Cytonics rejects venture capital, believing it stifles innovation and dilutes shareholder value. Instead, they rely on over $25 million raised from individual investors who prioritize genuine progress over quick exits. With a strong community of 7,000 shareholders, they emphasize equity crowdfunding as a pathway to democratized and collaborative biotech advancement.

#56 🚗 Our CEO Delivers A Quick Message From the Road!

Investor Relations, Joey BoseAugust 16, 2025644Views 0Likes 0Comments

The message emphasizes gratitude towards patients and investors who contribute to Cytonics’ mission. Highlighting milestones like treating over 10,000 patients and issuing 25 patents, it reinforces that Cytonics is community-driven and not just a typical biotech firm. The team appreciates all stakeholders and encourages further investment.

#55 🧬 Perfecting Nature’s Blueprint

Science CornerJuly 1, 2025390Views 0Likes 0Comments

Cytonics has developed CYT-108, a refined version of the naturally occurring protein Alpha-2-Macroglobulin (A2M), to combat osteoarthritis. By optimizing A2M for enhanced protease inhibition, the precision-engineered biologic minimizes side effects and maximizes therapeutic potential. It’s backed by extensive scientific validation and patented for patient safety and efficacy.

#53 🧪 The Experiment That Started It All

Our Story, Science CornerJune 25, 2025691Views 0Likes 0Comments

The journey of developing a cartilage-protecting therapy began with a hypothesis about the A2M protein’s potential. Initial experiments showed A2M could significantly reduce cartilage destruction caused by osteoarthritis. This led to the creation of APIC™ and the more advanced CYT-108, which demonstrated remarkable efficacy in preclinical trials, paving the way for human clinical trials.

#52 🥊 Positioned to Win: Why Cytonics Stands Out in the 2025 Biotech Landscape

Investor RelationsJune 9, 20251KViews 0Likes 0Comments

Cytonics aims to address osteoarthritis, impacting over 500 million globally, with its innovative CYT-108 therapy. Positioned strategically in capital markets, the company targets Phase 2-ready investments. With strong intellectual property and funding strategies, Cytonics is well-prepared for M&A opportunities, benefiting from current biotech trends and investor interests.

#64 ❤️‍🩹 Healthspan vs Lifespan The Future of Longevity with Cytonics

#63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD Approach

#62 🙏 Another Year Full of Gratitude

#61 🛑 Can We Stop Osteoarthritis Before It Starts?

#60 👎 Where Big Pharma Tried And Failed

#59 🧬 Why is A2M being called a physiological guardian?

#58 🚅 Inside the Engine Room: Progress Since Our $7M Raise

#57: 👎 Why Cytonics Turned Down VC

#56 🚗 Our CEO Delivers A Quick Message From the Road!

#55 🧬 Perfecting Nature’s Blueprint

#53 🧪 The Experiment That Started It All

#52 🥊 Positioned to Win: Why Cytonics Stands Out in the 2025 Biotech Landscape

Get fresh updates

Download Exclusive Investor Presentation & Stay Updated